5Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting the full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation, 1998,98 : 1597-1603.
6Horton JD, Bushwick BM. Warfarin therapy : evolving strategies in anticoagulation. Am Faro Physician, 1999,59:635-646.
7Sabeti S,Mlekusch W,Amighi J,et al. Primary patency of longsegment self-expanding nitinol stents in the femoropopliteal arteries. J Endovasc Ther,2005 ,12 :6-12.
8Dorffler-Melly J, Koopman MM, Prins MH, et al. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev ,2005 ,25 :CD002071.
9Gray BH, Sullivan TM, Childs MB, et al. High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long-segment superficial femoral artery disease after suboptimal angioplasty. J Vasc Surg, 1997,25:74-83.
10Schweizer J, Muller A, Forkman L, et al. Potential use of a low-molecular-weight heparin to prevent restenosis in patients with extensive wall damage following peripheral angioplasty. Angiology, 2001,52:659-669.
7Lensvelt MM,Reijnen MM,Wallis De Vries BM. Treatment strategies for extensive chronic SFA occlusions:indications and results[J].Journal of Cardiovascular Surgery(Torino),2012,(Suppl 1):161-170.
8Norgren L,Hiatt WR,Dormandy JA. Inter-Society consensus for the management of peripheral arterial disease (TASC Ⅱ)[J].European Journal of Vascular and Endovascular Surgery,2007,(Suppl 1):S1-75.
9Miyazaki M,Higashi Y,Goto C. Sarpogrelate hydrochloride,a selective 5-HT2A antagonist,improves vascular function in patients with peripheral arterial disease[J].Journal of Cardiovascular Pharmacology,2007.221-227.
10Hara H,0sakabe M,Kitajima A. MCI-9042,a new antiplatelet agent is a selective S2-serotonergic receptor antagonist[J].Thrombosis and Haemostasis,1991.415-420.
